Neurosense Therapeutics Ltd. (NRSN) AI Stock Analysis

• Market Cap: $31.78M
• Dividend Yield: N/A
• Average Volume (3M): 944.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: N/A
• EPS Growth: 31.09%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 29,699,320
• 10 Day Avg. Volume: 256,142
• 30 Day Avg. Volume: 944,423
• PEG Ratio: 0.06
• Price to Book (P/B): 8.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.20
• Enterprise Value/Market Cap: 1.49
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -5.54
• 1Y Price Target: $8.25
• Price Target Upside: 700.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $0.91 ▼(-11.65% Downside)

The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), which elevates funding and dilution risk. Technical signals are mixed with a weak longer-term trend despite neutral momentum, and valuation is limited by negative earnings and no dividend support.

Positive Factors

Regulatory Progress - Phase 3 Clearance

FDA clearance to start a pivotal Phase 3 (PARAGON) materially advances the company’s regulatory pathway, creating a defined route to potential approval. A successful pivotal program would de-risk the business model, enable partnering/licensing, and support longer-term commercialization planning.

Clinical Milestone - Data Collection Complete

Database lock on the Phase 2 RoAD study delivers a near-term, durable informational catalyst: final analyses will clarify efficacy signals and biomarker links. That clarity helps prioritize development decisions, inform regulatory strategy, and attract partners or investors over the coming months.

Favorable Safety Profile

A benign safety/tolerability profile in Phase 2 reduces clinical and regulatory risk across indications, improving the probability that PrimeC can advance to larger studies. Safer profiles expand eligible patient pools and enhance attractiveness for partners, aiding long-term development prospects.

Negative Factors

No Revenue / Widening Losses

Persistent pre-revenue status with materially widening losses increases structural funding dependence; sustained negative results limit reinvestment, constrain strategic optionality, and raise dilution risk if the company must raise capital to continue development beyond current programs.

Rising Cash Burn and Negative FCF

Escalating cash burn and persistently negative free cash flow create a durable financing requirement that pressures runway and strategic flexibility. Because cash losses track reported net losses, the company faces real funding needs that may force dilutive financings or constrained R&D pacing over months.

Equity-Based Compensation Signals Cash Constraints

Approving restricted shares in lieu of cash fees is a structural sign of liquidity prioritization: it preserves cash but increases potential share count. Over time, routine use of equity comp can dilute existing shareholders and reflects constrained cash resources affecting long-term capital structure.

Neurosense Therapeutics Ltd. Business Overview & Revenue Model

Company Description

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

How the Company Makes Money

Neurosense Therapeutics Ltd. generates revenue primarily through funding and partnerships related to its research and development activities. The company may secure revenue from licensing agreements, where larger pharmaceutical companies pay upfront fees, milestone payments, and royalties for the rights to develop and commercialize its drug candidates. Additionally, Neurosense might receive government grants or private funding to support its research initiatives. As its products progress through clinical trials and towards market approval, the company may also enter into strategic collaborations that contribute to its financial growth.

Neurosense Therapeutics Ltd. Financial Statement Overview

Summary

Income and cash flow quality are weak with zero revenue and widening losses alongside rising cash burn, implying continued reliance on external funding. The balance sheet has low leverage, but prior negative equity and a shrinking asset base increase dilution/financing risk.

Income Statement

The company has reported zero revenue across all provided annual periods (2019–2024), consistent with a pre-commercial biotech profile. Losses have widened materially versus earlier years, with net loss moving from about -$2.8M (2020) to roughly -$10.2M (2024), indicating an increasing cost base ahead of commercialization. Profitability is structurally weak (persistent negative gross profit and negative operating results), which is typical for the stage but leaves results highly dependent on future funding and clinical/regulatory outcomes.

Balance Sheet

Leverage appears low in the latest year, with total debt of ~$73K in 2024 and a low debt-to-equity ratio (~0.03), which reduces solvency risk. However, equity has been volatile—stockholders’ equity was negative in 2023 (about -$1.9M) before turning positive in 2024 (~$2.6M), highlighting potential dilution/restructuring risk and balance sheet instability. Total assets declined from ~11.4M (2021) to ~4.6M (2024), suggesting the asset base has been shrinking as cash is consumed.

Cash Flow

Cash burn is significant and rising: operating cash flow was about -$10.1M in 2024 versus -$8.4M in 2023 and -$0.7M in 2020. Free cash flow is similarly negative (about -$10.1M in 2024), indicating ongoing funding needs. A modest positive is that free cash flow broadly tracks reported net losses (free cash flow to net income near ~1x in recent years), suggesting losses are largely cash-based rather than being masked by large non-cash adjustments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	-89.00K	-3.00K	-3.00K
EBITDA	-8.55M	-9.88M	-9.64M	-12.23M	-2.88M	-2.83M
Net Income	-8.66M	-10.21M	-10.11M	-12.34M	-4.04M	-2.83M
Balance Sheet
Total Assets	1.68M	4.58M	3.18M	7.71M	11.43M	779.00K
Cash, Cash Equivalents and Short-Term Investments	666.00K	3.38M	2.64M	7.09M	11.06M	699.00K
Total Debt	0.00	73.00K	142.00K	211.00K	1.83M	0.00
Total Liabilities	2.20M	1.99M	4.94M	2.09M	2.42M	120.00K
Stockholders Equity	-519.00K	2.58M	-1.87M	5.62M	9.01M	659.00K
Cash Flow
Free Cash Flow	-2.00K	-10.14M	-8.38M	-7.66M	-1.56M	-704.00K
Operating Cash Flow	-2.00K	-10.13M	-8.35M	-7.59M	-1.54M	-695.00K
Investing Cash Flow	0.00	1.00K	3.47M	-3.54M	-17.00K	-9.00K
Financing Cash Flow	0.00	10.91M	3.98M	3.69M	11.90M	508.00K

Neurosense Therapeutics Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.03
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRSN, the sentiment is Neutral. The current price of 1.03 is above the 20-day moving average (MA) of 0.87, above the 50-day MA of 0.97, and below the 200-day MA of 1.30, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 60.74 is Neutral, neither overbought nor oversold. The STOCH value of 90.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NRSN.

Neurosense Therapeutics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TENX	55 Neutral	$114.07M	-16.11	-44.80%	―	―	92.89%
KZR	52 Neutral	$45.18M	-0.73	-56.86%	―	―	35.80%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XCUR	48 Neutral	$38.24M	-3.99	-217.87%	―	-100.00%	33.44%
NRXS	48 Neutral	$50.49M	-4.64	-3071.15%	―	36.89%	43.58%
CLGN	46 Neutral	$21.24M	-1.63	-92.74%	―	280.77%	32.82%
NRSN	44 Neutral	$31.78M	-1.83	―	―	―	31.09%

Neurosense Therapeutics Ltd. Corporate Events

NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash

On December 30, 2025, NeuroSense Therapeutics held a Special Meeting of Shareholders at which investors approved three equity-related resolutions: grants of restricted shares to the company’s non-management directors for 2024, additional restricted shares to those directors in lieu of deferred cash fees to preserve financial flexibility, and a grant of restricted shares to Chief Executive Officer and director Alon Ben-Noon. The decisions, formally reported on January 6, 2026, underscore NeuroSense’s continued use of equity-based compensation to conserve cash resources and align the interests of its leadership and board with those of shareholders.

The most recent analyst rating on (NRSN) stock is a Hold with a $0.74 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.

NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial

On December 22, 2025, NeuroSense Therapeutics reported that a safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC in Alzheimer’s disease showed a favorable tolerability profile, with no serious adverse events and no new or unexpected safety signals. As an exploratory trial, the clinical outcome measures are descriptive, and the company plans to interpret these clinical observations together with biomarker data, with combined clinical and biomarker results expected in the first quarter of 2026, potentially informing PrimeC’s future development path and NeuroSense’s positioning in the competitive Alzheimer’s drug development landscape.

The most recent analyst rating on (NRSN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.

NeuroSense Completes Data Collection for Alzheimer’s Trial

NeuroSense Therapeutics Ltd. announced the completion of data collection for its Phase 2 clinical trial of PrimeC in Alzheimer’s disease, known as the RoAD study, on December 8, 2025. The database lock signifies the trial’s readiness for final statistical analysis, with results anticipated in early 2026. This milestone could potentially enhance NeuroSense’s position in the neurodegenerative treatment market, offering insights into the efficacy of PrimeC and impacting stakeholders’ expectations.

The most recent analyst rating on (NRSN) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.

NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug

On December 4, 2025, NeuroSense Therapeutics announced plans for a pre-NDS meeting with Health Canada in April 2026 to discuss the regulatory advancement of PrimeC for ALS. The company is optimistic about the regulatory pathway in Canada and anticipates a potential NDS submission by mid-2026, which could impact its operations and market positioning positively.

The most recent analyst rating on (NRSN) stock is a Buy with a $7.50 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.

NeuroSense Gains FDA Approval for Phase 3 ALS Trial

NeuroSense Therapeutics Ltd. announced on November 24, 2025, that it has received FDA clearance to initiate a pivotal Phase 3 clinical trial for its lead drug candidate, PrimeC, for the treatment of ALS. This trial, named PARAGON, will be conducted in the U.S. and EU, involving 300 participants and aims to build on the promising results of the Phase 2b PARADIGM trial. The FDA’s clearance is a significant advancement for NeuroSense, potentially strengthening its position in the biotechnology industry and offering hope for ALS patients.

The most recent analyst rating on (NRSN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.

NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation

NeuroSense Therapeutics Ltd. has announced a Special Meeting of Shareholders scheduled for December 30, 2025, to discuss and vote on the approval of restricted share grants to non-management directors and the CEO, Alon Ben-Noon. These grants are intended as equity compensation to maintain financial flexibility and align management interests with those of shareholders. The Board of Directors unanimously recommends voting in favor of these proposals, which are seen as crucial for the company’s strategic financial management.

The most recent analyst rating on (NRSN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.